Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 6, 2015, Pages 438-443

  Vakiani, Efsevia ^a   Yaeger, Rona ^b   Brooke, Sylvester ^a   Zhou, Yi ^a   Klimstra, David S ^a   Shia, Jinru ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Departments of Psychiatry and Medicine   (United States)

Author keywords

BRAF V600E; colon cancer; immunohistochemistry; VE1 antibody

Indexed keywords

B RAF KINASE; BRAF V600E PROTEIN; MUTANT PROTEIN; PARAFFIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; CANCER ANTIBODY;

CANCER CELL; COLORECTAL CARCINOMA; COLORECTAL POLYP; COLORECTAL TUMOR; CONFERENCE PAPER; EVALUATION STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; AMINO ACID SUBSTITUTION; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CHEMISTRY; COLONIC POLYPS; COLORECTAL NEOPLASMS; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; MUTATION; PATHOLOGY; RETROSPECTIVE STUDY;

AMINO ACID SUBSTITUTION; ANTIBODIES, NEOPLASM; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; COLONIC POLYPS; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84937815186     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000116     Document Type: Conference Paper

References (28)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
2. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
3. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486.
4. Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91:355-358.
5. Vaughn CP, Zobell SD, Furtado LV, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50:307-312.
6. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30:2956-2962.
7. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.
8. Sinicrope FA, Foster NR, Yoon HH, et al. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012;30: 406-412.
9. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009;101:465-472.
10. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011-2019.
11. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063-6069.
12. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory meta-static colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-762.
13. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-5712.
14. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100-103.
15. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
16. Capper D, Voigt A, Bozukova G, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer. 2013;133:1624-1630.
17. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.
18. Preusser M, Capper D, Berghoff AS, et al. Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immuno-histochem Mol Morphol. 2013;21:159-164.
19. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397-405.
20. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123: 223-233.
21. Affolter K, Samowitz W, Tripp S, et al. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer. 2013;52:748-752.
22. Adackapara CA, Sholl LM, Barletta JA, et al. Immunohistochem-istry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology. 2013;63:187-193.
23. Thiel A, Heinonen M, Kantonen J, et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch. 2013;463:623-621.
24. Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohis-tochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 2013;37:1592-1602.
25. Busam KJ, Hedvat C, Pulitzer M, et al. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol. 2013;37:413-420.
26. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61-65.
27. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012;36:1796-1800.
28. Yancovitz M, Litterman A, Yoon J, et al. Intra-and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and meta-static melanoma. PLoS One. 2012;7:e29336.